US Patent 8,889,115: Scope, Claims, Expiration, and Patiromer Patent Landscape

US Patent No. 8,889,115 is a method-of-use patent directed to oral potassium removal with crosslinked cation-exchange polymers, including alpha-fluoroacrylic acid polymers. Its claims are closely associated with patiromer, the active polymer in Veltassa. The patent does not claim every potassium binder or every use of patiromer. Infringement requires satisfaction of specific patient, treatment, dosage-form, polymer-composition, and, for some claims, congestive-heart-failure conditions.

The patent’s broadest commercial relevance is its coverage of patiromer use in patients with renal insufficiency who are receiving drugs that increase hyperkalemia risk, including ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, heparin, and trimethoprim. Separate claims cover patiromer-type treatment in patients with congestive heart failure.

What does US Patent 8,889,115 protect?

US 8,889,115 protects selected methods of removing potassium from patients by administering an oral crosslinked cation-exchange polymer. The patent includes two principal claim groups:

Claims 1-10 and 17-25 cover a broader polymer genus defined by acid groups with an electron-withdrawing substituent at the alpha or beta carbon.
Claims 11-16 and 26-31 specifically cover crosslinked alpha-fluoroacrylic acid polymers.

The patent is therefore stronger as a use patent for a defined polymer class than as a general patent covering all potassium-binding drugs.

Claim group	Core subject matter	Key limitations
Claims 1-10	Potassium removal in renal-insufficiency patients	Oral dosage form; crosslinked cation-exchange polymer; acid group with alpha- or beta-electron-withdrawing substituent
Claims 11-16	Potassium removal with crosslinked alpha-fluoroacrylic acid polymer	Oral dosage form; therapeutically effective amount; renal insufficiency; specified concomitant medicines
Claims 17-25	Potassium removal in CHF patients	Oral dosage form; bead-form crosslinked cation-exchange polymer; electron-withdrawing substituent
Claims 26-31	Potassium removal in CHF patients using alpha-fluoroacrylic acid polymer	Oral dosage form; CHF; optional bead form and concomitant potassium-sparing therapy or ACE inhibitor

The claims are method claims. They do not independently claim a composition of matter, a manufacturing process, a specific dose, or a finished product formulation.

What are the independent claims in US 8,889,115?

Claim 1: renal insufficiency and concomitant-risk medicines

Claim 1 requires all of the following:

A patient in need of potassium removal.
Renal insufficiency.
Treatment of the renal insufficiency with at least one listed medicine.
Oral administration of a potassium-binding polymer.
A crosslinked cation-exchange polymer in bead form.
Acid groups in acid or salt form.
An electron-withdrawing substituent attached to a carbon atom alpha or beta to the acid group.

The listed medicines are:

Potassium-sparing diuretics.
ACE inhibitors.
ARBs.
NSAIDs.
Heparin.
Trimethoprim.

This claim is not limited expressly to hyperkalemia, although claim 9 adds hyperkalemia as a dependent limitation. A generic or competing product would not infringe claim 1 merely because it removes potassium. The accused use would need to involve the defined patient population, oral dosage form, bead form, polymer structure, and one of the specified concomitant medicines.

Claim 11: alpha-fluoroacrylic acid polymer

Claim 11 narrows the polymer to a crosslinked alpha-fluoroacrylic acid polymer. It also requires:

A patient with renal insufficiency.
Treatment with one of the specified medicines.
Oral administration.
A therapeutically effective amount.

Claims 12-14 further narrow the polymer by requiring:

A swelling ratio below 3.
One or more specified crosslinkers.
Bead form.

This claim set is technically important because it moves from a functional or structural genus to a specific fluorinated acrylic-acid polymer architecture.

Claim 17: CHF patient and broader polymer genus

Claim 17 covers potassium removal in a patient suffering from CHF. It requires:

Oral administration.
A bead-form crosslinked cation-exchange polymer.
Acid groups in acid or salt form.
An alpha- or beta-electron-withdrawing substituent.

Unlike claim 1, claim 17 does not require renal insufficiency or treatment with one of the listed medicines. Claims 22-25 add potassium-sparing diuretics, ACE inhibitors, and simultaneous administration.

Claim 26: CHF and alpha-fluoroacrylic acid polymer

Claim 26 covers oral administration of a crosslinked alpha-fluoroacrylic acid polymer to a patient suffering from CHF. Claims 27-29 add the swelling-ratio, crosslinker, and bead-form limitations.

Claims 26-31 are potentially significant because the independent claim does not require renal insufficiency, a specified concomitant medicine, or simultaneous administration.

How do the dependent claims narrow the patent scope?

The dependent claims create multiple fallback positions if a broad claim is challenged.

Dependent claims	Limitation added	Commercial or litigation relevance
2, 18	Hydroxyl, ether, ester, or halide electron-withdrawing group	Defines permitted substituent classes
3, 19	Carboxylic acid group	Targets carboxylate-based polymers
4, 20	Phosphonic acid group	Preserves a non-carboxylic polymer embodiment
5, 21	Alpha-fluoro carboxylic polymer	Closely tracks the fluorinated polymer species
6	Ca2+ counterion	Relevant to calcium-form potassium binders
7, 15, 23	ACE-inhibitor therapy	Covers a major hyperkalemia-risk population
8, 16	ARB therapy	Covers another renin-angiotensin-system treatment population
9	Hyperkalemia	Adds the clinical condition most directly associated with Veltassa
10, 24, 25	Simultaneous administration	Raises issues concerning co-administration and label instructions
12, 27	Swelling ratio below 3	Adds a measurable polymer-performance limitation
13, 28	Specified crosslinkers	Creates composition-specific fallback claims
14, 29	Bead form	Narrows dosage form and particle morphology

The Ca2+ limitation in claim 6 is particularly relevant to patiromer. FDA labeling identifies Veltassa as patiromer, a nonabsorbed potassium-binding polymer administered as an oral powder that is mixed with water before administration.[2] The patent claims, however, use "bead form" in several places. Product-to-claim mapping therefore depends on how the commercial material is manufactured and characterized, not only on its active ingredient name.

Is US 8,889,115 a composition patent or a method-of-use patent?

US 8,889,115 is principally a method-of-use patent.

It does not broadly claim:

Patiromer as a standalone chemical composition.
Every calcium-containing potassium-binding polymer.
Every oral potassium-binding polymer.
Every use of patiromer for hyperkalemia.
The Veltassa trade dress, package, or manufacturing process.

Its infringement theory depends on the use made of the product. A generic applicant could attempt to avoid liability by omitting or carving out patented indications from its labeling. That strategy is evaluated under the Hatch-Waxman framework and under induced-infringement principles, including whether the proposed label encourages the patented use.

A product can also face risk if its label, promotional materials, dosing instructions, or clinical positioning encourage a claimed use even when the ANDA omits an express indication.

What polymer structure does the patent cover?

The central structural concept is an acid-functionalized crosslinked cation-exchange polymer in which an electron-withdrawing substituent is attached to the carbon alpha or beta to the acid group.

The claims expressly identify:

Hydroxyl substituents.
Ether groups.
Ester groups.
Halides.
Carboxylic acid groups.
Phosphonic acid groups.
Alpha-fluoroacrylic acid polymers.

The fluorine limitation is the most commercially focused embodiment. Alpha-fluoroacrylic acid polymers have a fluorine atom adjacent to the carboxylic acid functionality. In the claimed polymer, crosslinking may use divinylbenzene, ethylene bisacrylamide, N,N'-bis(vinylsulfonylacetyl)ethylenediamine, 1,3-bis(vinylsulfonyl)-2-propanol, vinylsulfone, N,N'-methylenebisacrylamide, polyvinyl ether, polyallyl ether, or combinations of those materials.

The specification and claims indicate that the patent is directed to polymer chemistry intended to control potassium exchange, swelling, and gastrointestinal performance. Claim 12 and claim 27 make swelling ratio a claim boundary. A competitor using a chemically different polymer, a nonfluorinated polymer, or a materially different crosslinking system may have a stronger noninfringement position.

Does the patent cover patiromer and Veltassa?

The patent is highly relevant to patiromer and Veltassa. Veltassa is FDA-approved for the treatment of hyperkalemia in adults and is administered orally.[2] Patiromer is a nonabsorbed potassium-binding polymer that exchanges calcium for potassium in the gastrointestinal tract.

The claims appear designed to cover clinical use of a patiromer-type fluorinated cation-exchange polymer in populations at elevated risk of hyperkalemia, particularly patients receiving renin-angiotensin-aldosterone-system medicines. The strongest product-use overlap is likely found in:

Adults with chronic kidney disease or renal insufficiency.
Patients receiving ACE inhibitors or ARBs.
Patients receiving potassium-sparing diuretics.
Patients with CHF.
Patients treated for hyperkalemia with an oral calcium-containing potassium binder.

The claims should not be treated as proof that every Veltassa use infringes. The label, patient diagnosis, concomitant medicines, polymer morphology, and dosage form must align with the limitations of a particular claim.

What is the expiration date of US Patent 8,889,115?

The patent claims priority to September 17, 2007. On that priority basis, the nominal 20-year patent term runs to September 17, 2027, subject to any applicable patent-term adjustment or extension recorded in the official patent and Orange Book records.[1][3]

Milestone	Date
Earliest stated priority	September 17, 2007
US patent issuance	November 18, 2014
Base 20-year term from earliest priority	September 17, 2027
Potential term adjustment or extension	Must be determined from the official record
Practical generic-entry analysis	Depends on listed patents, statutory exclusivity, litigation, and any settlement

The patent should be analyzed as one part of the Veltassa estate. Other patents may expire later and may cover formulations, dosing, particle characteristics, manufacturing, or additional methods of use. A generic launch after this patent’s base term could still face other listed or asserted patents.

What is the Orange Book status of US 8,889,115?

Patiromer is an FDA-approved small-molecule-associated polymer drug rather than a biologic. The relevant product pathway is an ANDA, not a biosimilar application. Patents listed for Veltassa are recorded in the FDA Orange Book when the NDA holder identifies them as covering the drug substance, drug product, or an approved method of use.[3]

The Orange Book analysis should separate three issues:

Whether US 8,889,115 is currently listed against Veltassa.
Which approved-use codes are associated with the listing.
Whether the patent has expired, been delisted, or remains relevant to an ANDA Paragraph IV certification.

A Paragraph IV certification would assert that the listed patent is invalid, unenforceable, or not infringed. If the NDA holder files a timely infringement action, FDA approval may be subject to the statutory 30-month stay under the Hatch-Waxman Act.[4]

What Paragraph IV challenges affect patiromer?

Patiromer is exposed to ANDA-based generic competition rather than biosimilar competition. A generic applicant could challenge US 8,889,115 through:

Paragraph IV certification.
A section VIII statement carving out patented methods of use.
A Paragraph III certification accepting delay until patent expiration.
A non-infringement position based on a different polymer, dosage form, indication, or label.

For this patent, a Paragraph IV strategy would likely focus on:

Anticipation or obviousness of the claimed fluorinated polymer methods.
Written-description or enablement issues for the broader electron-withdrawing-substituent genus.
Whether the accused polymer is an alpha-fluoroacrylic acid polymer.
Whether the commercial product is administered in the claimed bead form.
Whether the patient population and concomitant medicines are required by the proposed label.
Whether simultaneous administration is actually encouraged.

The dependent claims provide the patent holder with narrower positions if the broad genus claims are vulnerable. A challenge that defeats claim 1 may not defeat claim 11, and a challenge to claims 1 and 11 may not eliminate claims 17 or 26.

Which companies compete with patiromer?

The principal branded comparator is sodium zirconium cyclosilicate, marketed as Lokelma by AstraZeneca. Sodium polystyrene sulfonate, including Kayexalate and generic products, is an older potassium-binding resin. The products differ materially in polymer chemistry, counterion, onset, dosing, drug-separation instructions, and patent position.

Product	Active technology	FDA pathway	Patent-risk profile
Veltassa	Patiromer, calcium-containing polymer	NDA	Method-of-use, polymer, formulation, and manufacturing estate
Lokelma	Sodium zirconium cyclosilicate	NDA	Inorganic crystal composition and method patents; separate estate
Kayexalate/generics	Sodium polystyrene sulfonate	Legacy/generic products	Older and more fragmented patent position
Patiromer generic	Same or equivalent polymer product	ANDA	Paragraph IV and formulation/process risks

Biosimilar risk is not the relevant pathway for Veltassa. Because patiromer is not a therapeutic protein, competitors would generally pursue an ANDA, subject to demonstrating pharmaceutical equivalence and bioequivalence or satisfying FDA requirements applicable to locally acting nonabsorbed products.

How strong is the patent estate for Veltassa?

US 8,889,115 is commercially meaningful but should not be viewed in isolation. Its strength comes from the combination of:

A clinically defined renal-insufficiency population.
Specified concomitant medicines.
An oral dosage form.
A crosslinked cation-exchange polymer.
Fluorinated acrylic-acid chemistry.
CHF-specific method claims.
Dependent limitations covering swelling ratio, crosslinker identity, bead form, and calcium counterion.

Its principal weaknesses are structural and proof-related:

Several claims require facts about the patient’s concurrent treatment.
Method infringement may depend on the actual label and prescribing behavior.
"Bead form" may require technical evidence concerning the product’s morphology.
The broad genus in claims 1 and 17 may face prior-art and written-description scrutiny.
The patent does not by itself block all noninfringing potassium-binding technologies.

The patent is strongest against a generic that reproduces the patiromer polymer and markets the product for the same renal-insufficiency and CHF populations. It is weaker against a product that uses a different polymer platform, avoids the claimed fluorinated structure, or limits its label to nonclaimed uses.

What generic launch scenarios exist for patiromer?

Launch after patent expiration

A generic applicant may accept the patent and launch after the relevant patent term expires. This is the lowest litigation-risk pathway but delays market entry.

Paragraph IV challenge

A successful Paragraph IV challenge could permit earlier approval and launch. The applicant would need to overcome validity, enforceability, and infringement arguments for US 8,889,115 and other Veltassa patents.

Section VIII carve-out

A label carve-out could remove one or more patented indications. This strategy is difficult where the remaining label, dosing instructions, or physician use still encourages the claimed method.

Settlement-based launch

A settlement may establish an agreed entry date before the latest patent expiration. Commercial terms can include authorized generic arrangements, licensing, supply agreements, or restrictions on indication labeling. Settlement analysis requires the actual agreement and any Federal Trade Commission or court filing; the patent number alone does not establish settlement terms.

What licensing and ownership history affects the patent?

Relypsa developed patiromer and obtained FDA approval for Veltassa. Galenica, now Vifor Pharma and part of CSL, acquired Relypsa in 2016. The acquisition transferred the commercial and patent interests associated with Veltassa to the acquiring group.[5]

The ownership history matters because patent assignment records, NDA ownership, Orange Book listing decisions, and litigation authority may differ over time. A change in patent ownership does not alter the claim scope, but it can affect enforcement, licensing, and the identity of the party responding to Paragraph IV notices.

What manufacturing and IP barriers remain after US 8,889,115?

A generic manufacturer must address more than the claimed clinical method. Relevant technical barriers include:

Reproducing the crosslinked fluorinated polymer.
Controlling bead size and morphology.
Achieving the claimed swelling ratio.
Selecting and controlling crosslink density.
Maintaining the proper calcium counterion.
Establishing pharmaceutical equivalence for an orally administered, nonabsorbed polymer.
Demonstrating batch-to-batch potassium-binding performance.
Avoiding separate process, formulation, and particle-size patents.

The manufacturing process may be difficult to design around even if US 8,889,115 is invalidated or expires. Conversely, a technically equivalent product may still face a noninfringement argument if it is supplied with a properly carved-out label and is not promoted for the patented populations.

Key Takeaways

US 8,889,115 is a method-of-use patent, not a universal composition patent for potassium binders.
Claims 1 and 11 focus on renal-insufficiency patients treated with specified hyperkalemia-risk medicines.
Claims 17 and 26 focus on patients with CHF and do not require every limitation found in the renal-insufficiency claims.
The alpha-fluoroacrylic acid polymer claims are the most direct technical overlap with patiromer.
Calcium counterion, bead form, swelling ratio, and crosslinker identity create important dependent-claim positions.
The base term based on the stated 2007 priority is September 17, 2027, subject to any recorded patent-term adjustment or extension.
Generic competition would proceed through the ANDA pathway, not the biosimilar pathway.
A Paragraph IV challenge would likely target polymer identity, bead form, claim construction, prior art, and label-induced infringement.
Veltassa’s broader patent estate remains relevant after analyzing this patent because later-expiring formulation, manufacturing, or method patents may control actual generic entry.
Vifor Pharma, now within CSL, holds the principal commercial interest following the acquisition of Relypsa.

FAQs

Is US 8,889,115 limited to hyperkalemia treatment?

No. Hyperkalemia is expressly added in dependent claim 9, but the independent claims recite removal of potassium from a patient in need thereof. The clinical label and treatment context remain important to infringement analysis.

Does a generic patiromer product automatically infringe this patent?

No. Infringement depends on the generic product’s polymer structure, dosage form, label, patient population, concomitant medicines, and promoted uses. Other Veltassa patents may create separate risks.

Does claim 6 cover every calcium-containing potassium binder?

No. Claim 6 depends on claim 1 and requires the other limitations of claim 1, including the defined crosslinked polymer, bead form, patient population, oral dosage form, and concomitant treatment.

Can a competitor avoid the patent by using sodium instead of calcium?

Potentially, but not automatically. The calcium limitation appears only in dependent claim 6. Claims without that limitation may still be asserted if the competitor’s polymer and use satisfy their separate requirements.

Is a CHF-only patiromer label outside the patent?

No. Claims 17 and 26 independently address patients suffering from CHF. A CHF-focused label could still implicate those claims even if it omits renal insufficiency or the listed concomitant medicines.

References

United States Patent and Trademark Office. (2014). U.S. Patent No. 8,889,115, methods for removing potassium from a patient.
U.S. Food and Drug Administration. (2023). Veltassa (patiromer) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Code. (2023). 21 U.S.C. § 355(j): Abbreviated applications and patent certifications.
CSL Limited. (2016). CSL completes acquisition of Relypsa, Inc.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1732523	⤷ Start Trial	300924	Netherlands	⤷ Start Trial
European Patent Office	2269589	⤷ Start Trial	CA 2018 00003	Denmark	⤷ Start Trial
European Patent Office	1732523	⤷ Start Trial	300925	Netherlands	⤷ Start Trial
European Patent Office	1732523	⤷ Start Trial	122018000011	Germany	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,889,115

Summary for Patent: 8,889,115